| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6509038 | SEBELA IRELAND LTD | Antifungal compositions with improved bioavailability |
May, 2017
(6 years ago) | |
| US7081255 | SEBELA IRELAND LTD | Antifungal compositions with improved bioavailability |
May, 2017
(6 years ago) | |
| US8591948 | SEBELA IRELAND LTD | Antifungal compositions with improved bioavailability |
May, 2017
(6 years ago) | |
| US8486456 | SEBELA IRELAND LTD | Itraconazole compositions with improved bioavailability |
Oct, 2028
(4 years from now) | |
Onmel is owned by Sebela Ireland Ltd.
Onmel contains Itraconazole.
Onmel has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Onmel are:
- US6509038
- US7081255
- US8591948
Onmel was authorised for market use on 29 April, 2010.
Onmel is available in tablet;oral dosage forms.
Onmel can be used as onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks.
The generics of Onmel are possible to be released after 03 October, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2013 |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 29 April, 2010
Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks
Dosage: TABLET;ORAL
ONMEL family patents
